Evolving Brand-Name and Generic Drug Competition May Warrant a Revisionof the Hatch-Waxman Act
The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act’s intended balance of incentives for cost savings and continued innovation has been achieved.
Generic drug usage and challenges to brand-name drugs’ patents have increased markedly, resulting in greatly increased cost savings but also potentially reduced incentives for innovators. Congress should review whether Hatch-Waxman is achieving its intended purpose of balancing incentives for generics and innovation. It also should consider whether the law should be amended so that some of its provisions are brought more in line with recently enacted legislation governing approval of so-called biosimilars, or the corollary for biologics of generic competition for small-molecule drugs.
This study was not funded by the Robert Wood Johnson Foundation, but is being made available as an additional resource on this topic.
- 1. How the Health and Community Development Sectors are Combining Forces to Improve Health and Well-Being
- 2. Building the Scaffold to Improve Health Care to Advance Americans' Health
- 3. Partnerships Among Community Development, Public Health, and Health Care Could Improve the Well-Being of Low-Income People
- 4. Despite Obstacles, Considerable Potential Exists for More Robust Federal Policy on Community Development and Health
- 5. Bringing Researchers and Community Developers Together to Revitalize a Public Housing Project and Improve Health
- 6. Community Health Centers and Community Development Financial Institutions
- 7. Training New Community Health, Food Service, and Environmental Protection Workers Could Boost Health, Jobs, and Growth
- 8. The PROMETHEUS Bundled Payment Experiment
- 9. Mayo Clinic Employees Responded to New Requirements for Cost Sharing by Reducing PossiblyUnneeded Health Services Use
- 10. Gaps in Residency Training Should be Addressed to Better Prepare Doctors for a Twenty-First-Century Delivery System
- 11. How the National Prevention Council Can Overcome Key Challenges and Improve Americans' Health
- 12. Evolving Brand-Name and Generic Drug Competition May Warrant a Revisionof the Hatch-Waxman Act
- 13. Strengthening Children's Oral Health